Abstract
AbstractThis paper provides an overview of approaches to the allocation of scarce vaccine doses during a pandemic. Price and non-price methods are outlined to determine whom to prioritize. It is argued that depending on viral and vaccine properties, it may be superior to use epidemiological criteria than health risk criteria for prioritization. The paper concludes by noting that the key trade-offs between health risk and epidemiological properties have received too little study to systematically inform allocation during a public health emergency. Moreover, the evaluation criteria for vaccines themselves need to be adjusted to take potential short-term scarcity into account.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
